MAP2K7 and cancer: Since IL-2- and IL-15- pre-activated NK cells may be used in protocols of adoptive immunotherapy in cancer patients, we further investigated the effect of BRAF-i and MEK-i on NK cells that had been pre-activated for 2 days with IL-2 or IL-15.